NEW YORK (GenomeWeb) – Immunoassay developer PhasiQ this week received a two-year grant from the National Science Foundation to develop and commercialize an ELISA-based multiplex protein biomarker test for identifying patients with deep vein thrombosis (DVT).

The effort marks the company's ongoing effort to expand its offerings beyond do-it-yourself immunoassay kits and into pre-designed research tests for disease biomarkers and, ultimately, point-of-care diagnostics, John Dishinger, PhasiQ's director of product development, told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.